ライフサイエンスコーパス: fasting glucose

1 ubstantial weight loss and reduced HbA1c and fasting glucose.

2 pite weight gain, KCl prevented worsening of fasting glucose.

3 n cholesterol, central obesity, and elevated fasting glucose.

4 three primary outcomes were weaker than for fasting glucose.

5 diabetes and 266 participants with impaired fasting glucose.

6 45 matched controls with normal predonation fasting glucose.

7 des, high sensitivity C-reactive protein, or fasting glucose.

8 ven after multivariable adjustment including fasting glucose.

9 d thickness, waist circumference, height and fasting glucose.

10 ent of familial diabetes, sex, age, BMI, and fasting glucose.

11 astolic blood pressure, body mass index, and fasting glucose.

12 tension, dyslipidemia, diabetes, or impaired fasting glucose.

13 olesterol, high blood pressure, and elevated fasting glucose.

14 s2282679 with any other traits and diseases: fasting glucose (0.00 mmol/l [95% CI -0.01, 0.01]; p = 1

15 olesterol showed associations with increased fasting glucose (0.09 mmol/L, 95% CI 0.02 to 0.15), body

16 1 kg/m(2) genetically elevated BMI increased fasting glucose (0.18 mmol/l; 95% confidence interval (C

17 ydrate with SFA had no significant effect on fasting glucose (+0.02 mmol/L, 95% CI = -0.01, +0.04; n

18 se or fasting glucose>/=126 mg/dL and IFG as fasting glucose 100-125 mg/dL.

19 multiply by 0.0259]; 95% CI, 2.70 to 4.63), fasting glucose (-2.16 mg/dL [to convert to millimoles p

20 There were no changes in weight, fasting glucose, 2-h glucose and insulin, haemoglobin A1

21 es), and glycaemic traits (concentrations of fasting glucose, 2-h glucose, fasting insulin, and HbA1c

22 al bypass group showed greater reductions in fasting glucose (22% vs 6% in control group, P < 0.05) a

23 d lower HbA1c (6.2 vs 7.8, P = 0.002), lower fasting glucose (99.5 vs 157; P = 0.0068), and fewer T2D

24 Compared with donors with normal fasting glucose, a higher proportion of IFG donors had d

25 s not significantly associated with abnormal fasting glucose after considering the influence of OSA.

26 ) had impaired glucose tolerance or impaired fasting glucose and 171 entered the trial.

27 betics and 50 prediabetics (17 with impaired fasting glucose and 33 with impaired glucose tolerance).

28 identified three transcripts associated with fasting glucose and 433 transcripts associated with fast

29 orted diabetes or diagnostic levels for both fasting glucose and calibrated HbA1c).

30 living kidney donors often revert to normal fasting glucose and do not seem to have a significantly

31 sed red meat was associated with both higher fasting glucose and fasting insulin concentrations after

32 F, we detected an interaction effect between fasting glucose and fasting triglycerides with rs9939609

33 Likewise, changes in fasting glucose and fructosamine levels were similar.

34 Changes from entry to week 12 in fasting glucose and glucose area under the curve on 2-ho

35 Laboratory status was improved, for example, fasting glucose and glycated hemoglobin decreased from 6

36 ] with SCT) with 9062 concurrent measures of fasting glucose and HbA1c levels.

37 in the Si and AIR, along with an increase in fasting glucose and HbA1c.

38 and donor pairs showed significantly higher fasting glucose and hypertension in nondonors.

39 late cyclase 5, are associated with elevated fasting glucose and increased type 2 diabetes (T2D) risk

40 ated in genome-wide association studies with fasting glucose and insulin (FI).

41 e showed a graded positive relationship with fasting glucose and insulin (P<0.001).

42 Fasting glucose and insulin are intermediate traits for

43 even on the chow diet; HFD further increased fasting glucose and insulin but not glucose intolerance.

44 and the interaction of meat with genotype on fasting glucose and insulin concentrations in Caucasians

45 The association of higher fasting glucose and insulin concentrations with meat con

46 to fasting glucose or insulin resistance on fasting glucose and insulin concentrations.

47 ed meat and unprocessed red meat intake with fasting glucose and insulin concentrations; and 2) the i

48 Additionally, PTG deletion reduced fasting glucose and insulin levels in obese mice while i

49 n urban areas, is negatively associated with fasting glucose and insulin levels, but most aspects of

50 We conclude that at real-life fasting glucose and insulin levels, type 1 diabetes is a

51 on remained significant after adjustment for fasting glucose and insulin levels.

52 onship between elevated lactate and impaired fasting glucose and insulin resistance.

53 After including fasting glucose and insulin the association became non-s

54 els, morning plasma ACTH and serum cortisol, fasting glucose and insulin, and lipid parameters were d

55 We have identified multiple QTLs for fasting glucose and lipid levels.

56 Fasting glucose and lipid metabolism, and body weight of

57 The ADII was also adversely associated with fasting glucose and postload glucose but not with glycat

58 es, blood pressure, glycated hemoglobin, and fasting glucose and report the prevalence of abnormal va

59 Baseline fasting glucose and rs9939609 interacted on weight chang

60 Both HFD and Pb increased fasting glucose and serum leptin levels.

61 A significant correlation between fasting glucose and triglyceride levels was also observe

62 y, we investigated the interaction effect of fasting glucose and triglyceride levels with rs9939609 i

63 O) criteria to define GDM: >/=7.0 mmol/L for fasting glucose and/or >/=7.8 mmol/L for 2-h post-glucos

64 IGR was defined as impaired fasting glucose and/or impaired glucose tolerance, and h

65 tension and smoking, higher body mass index, fasting glucose, and 10-year risk for CVD.

66 such as blood pressure, cholesterol levels, fasting glucose, and body mass index.

67 sity lipoprotein cholesterol, triglycerides, fasting glucose, and fasting insulin.

68 six regions), measures of glycaemia (HbA1c, fasting glucose, and insulin concentrations, and Homeost

69 t of this variant on changes in body weight, fasting glucose, and insulin resistance in the Preventin

70 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin were abstracted by 2 indepe

71 ospective cohort, concentrations of 11 PFAS, fasting glucose, and lipids were measured in maternal mi

72 Processed meat was associated with higher fasting glucose, and unprocessed red meat was associated

73 al, HDL, and LDL cholesterol; triglycerides; fasting glucose; AST; and ALT levels were analyzed on a

74 (57.8%) of IFG donors had reverted to normal fasting glucose at a mean follow-up of 10.4 years.

75 ere aged 42-60 y and free of T2D or impaired fasting glucose at baseline in 1984-1989.

76 Lower FG fasting glucose at BR was more commonly associated with

77 vity, total cholesterol, blood pressure, and fasting glucose at goal levels.

78 Fasting glucose at re-assessment was also predictive of

79 elated variables (hemoglobin A1c [HbA1c] and fasting glucose) at baseline and with 6-month change in

80 n of patients achieving HbA1c below 6.5% and fasting glucose below 126 mg/dL was higher following RYG

81 Allele C at rs3093059 was associated with fasting glucose (beta = 0.20, P = 0.045) and G at rs1205

82 The primary outcome was the change in fasting glucose between groups from preintervention to p

83 l, body mass index, diet, physical activity, fasting glucose, blood pressure, and smoking were define

84 d race and factors including biological (eg, fasting glucose, body mass index), neighborhood (racial

85 otein- and total cholesterol, triglycerides, fasting glucose, body mass index, waist circumference, h

86 the proportion of participants with impaired fasting glucose but not a clinical diagnosis of diabetes

87 rol seem to be protective against increasing fasting glucose but not against type 2 diabetes.

88 The C-statistics were 0.662 for ADA fasting glucose clinical concentration categories and 0.

89 130 non-Western immigrants with prediabetes (fasting glucose concentration >5.5 mmol/L or random gluc

90 We compared prediabetes definitions based on fasting glucose concentration (American Diabetes Associa

91 ation and HbA1c were measured at visit 2 and fasting glucose concentration and 2 h glucose concentrat

92 -mmol/L (95% CI: 0.023, 0.051-mmol/L) higher fasting glucose concentration and a 0.049-ln-pmol/L (95%

93 Fasting glucose concentration and HbA1c were measured at

94 of intake, was inversely related to age and fasting glucose concentration and showed a nonlinear rel

95 erotic cardiovascular disease, 0.701 for ADA fasting glucose concentration clinical categories and 0.

96 ripheral arterial disease, and 0.683 for ADA fasting glucose concentration clinical categories and 0.

97 ent chronic kidney disease was 0.636 for ADA fasting glucose concentration clinical categories and 0.

98 ucose concentration clinical categories, WHO fasting glucose concentration clinical categories, and A

99 ADA fasting glucose concentration clinical categories, WHO f

100 [9%] of 10 844 people; 8.4-9.5), and the WHO fasting glucose concentration cutoff (1213 [11%] of 10 8

101 Prediabetes defined using the ADA fasting glucose concentration cutoff (prevalence 4112 [3

102 tration (American Diabetes Association [ADA] fasting glucose concentration cutoff 5.6-6.9 mmol/L and

103 concentration cutoff 5.6-6.9 mmol/L and WHO fasting glucose concentration cutoff 6.1-6.9 mmol/L), Hb

104 The definition of prediabetes using the ADA fasting glucose concentration cutoff was more sensitive

105 A fasting glucose concentration of 5.4 mmol/L or a 2 h pos

106 ion of 6.5% or less (</=47.5 mmol/mol) and a fasting glucose concentration of 5.6 mmol/L or less with

107 were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-

108 were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-

109 s different prediabetes definitions based on fasting glucose concentration, HbA1c, and 2 h glucose co

110 al disease, and all-cause mortality than did fasting glucose concentration-based definitions (all p<0

111 or change during follow-up) and for elevated fasting glucose concentrations (odds ratio, 1.46; 95% CI

112 h younger and older mothers had higher adult fasting glucose concentrations (roughly 0.05 mmol/L).

113 hance both glucagon and insulin secretion at fasting glucose concentrations and that FFAR1 and enhanc

114 D1/4KO mice displayed normal fasting glucose concentrations but had reduced tolerance

115 type 2 diabetes were identified: 55 had high fasting glucose concentrations only, 148 had high 2 h co

116 diabetes diagnosed on the basis of increased fasting glucose concentrations or 2 h glucose concentrat

117 Mean 12-month changes in fasting glucose concentrations were 0.33 mmol/L (5.5%) i

118 We have also shown that fat mass and fasting glucose concentrations were lower in TRPC1 KO mi

119 o three subgroups: diagnosed on the basis of fasting glucose concentrations, diagnosed on the basis o

120 d whether patients diagnosed on the basis of fasting glucose concentrations, those diagnosed on the b

121 mulates secretion of glucagon and insulin at fasting glucose concentrations.

122 with impaired glucose tolerance or impaired fasting glucose determined by oral glucose tolerance tes

123 sterol, low-density lipoprotein cholesterol, fasting glucose, diabetes mellitus, glycohemoglobin, bod

124 ns to 2020 suggest that obesity and impaired fasting glucose/diabetes mellitus could increase to affe

125 h adjustment for BMI, the change in maternal fasting glucose did not differ significantly between tre

126 and adipose tissue (G4Tg) exhibit increased fasting glucose disposal and thus lowered blood glucose.

127 pcidin fivefold and led to a 40% increase in fasting glucose due to insulin resistance, as confirmed

128 lutamyltransferase, and fatty liver, whereas fasting glucose, estimated glomerular filtration rate, a

129 ociation between R3527Q variant and impaired fasting glucose, fasting glucose or insulin, or oral glu

130 protein), adipokines (leptin, adiponectin), fasting glucose, fasting insulin, and HOMA-IR values wer

131 t, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months

132 The changes in fasting glucose, fasting insulin, insulin resistance (ho

133 were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI).

134 Whether loci that influence fasting glucose (FG) and fasting insulin (FI) levels, as

135 2 diabetes (T2D)-related quantitative traits fasting glucose (FG) and insulin (FI) in African ancestr

136 ounded estimates of the influence of T2D and fasting glucose (FG) on CHD risk.

137 CB0313.1 improved diabetic markers (fasting glucose, glucose tolerance, insulin tolerance, G

138 tent variable for glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosami

139 Cholesterols, fasting glucose, glycosylated haemoglobin, and proinflam

140 rance (OR 3.5, CI 1.2-9.9, P=0.01), as was a fasting glucose greater than 5.6 mmol/L (OR 4.8, CI 1.6-

141 ore of five components present at diagnosis: fasting glucose > 100 mg/dL or diabetes; elevated blood

142 included female sex, body mass index >/=35, fasting glucose >5.5 mmol/L, and many ballooned cells, N

143 ients (55%) had either undiagnosed diabetes (fasting glucose >7.0 mmol/L, n=4) or insulin resistance

144 = 0.93, 95% CI = 0.88 to 0.97) with elevated fasting glucose (>/= 110 mg/dL) after adjustment for clu

145 no hypoglycemic medication use) or abnormal fasting glucose (>/=100 mg/dl and/or hypoglycemic medica

146 d diabetes was defined as elevated levels of fasting glucose (>/=7.0 mmol/L [>/=126 mg/dL]) and hemog

147 tes was defined by history/medication use or fasting glucose>/=126 mg/dL and IFG as fasting glucose 1

148 In unadjusted GEE analyses, for a given fasting glucose, HbA1c values were statistically signifi

149 erived from principal components analysis of fasting glucose, HDL cholesterol, triglycerides, and blo

150 aortic pulse wave velocity, blood pressure, fasting glucose, HDL, LDL, or C-reactive protein.

151 mpared with reference definitions defined by fasting glucose, hemoglobin A1c, and medication use obta

152 with IR-related traits, including increased fasting glucose, hemoglobin A1C, total and LDL cholester

153 unspecified subtypes of MDD with changes of fasting glucose, high-density lipoprotein-cholesterol, t

154 ts provide evidence that p16(Ink4a) controls fasting glucose homeostasis and could as such be involve

155 fflux capacity after adjusting for age, sex, fasting glucose, homeostasis model assessment of insulin

156 alcohol use, hypertension, diabetes/impaired fasting glucose, homeostatic model assessment of insulin

157 was associated with development of impaired fasting glucose (IFG) after atenolol treatment.

158 factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV-infected multiethni

159 their association with diabetes and impaired fasting glucose (IFG) in Fukuoka, Japanese subjects (n =

160 iabetes can be identified as either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT

161 This study assessed whether impaired fasting glucose (IFG), insulin resistance, and waist-to-

162 treatment of asymptomatic diabetes, impaired fasting glucose (IFG), or impaired glucose tolerance (IG

163 beta-cell function in subjects with impaired fasting glucose (IFG).

164 from 1994 to 2007 with predonation impaired fasting glucose (IFG).

165 10.7), 18% of the participants had impaired fasting glucose (IFG; i.e., 100-125 mg/dL FBG) at first

166 case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjects) from

167 of 4 screening tests in identifying impaired fasting glucose, impaired glucose tolerance (IGT), and N

168 iewed the evidence on screening for impaired fasting glucose, impaired glucose tolerance, and type 2

169 th cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 d

170 patients (n = 28) met criteria for impaired fasting glucose/impaired glucose tolerance or diabetes.

171 olerance: normal glucose tolerance, impaired fasting glucose/impaired glucose tolerance, or diabetes.

172 Salsalate treatment increased VO2, lowered fasting glucose, improved glucose tolerance, and led to

173 A was significantly associated with abnormal fasting glucose in African Americans (odds ratio, 2.14;

174 usly unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variatio

175 he effect of a probiotic capsule on maternal fasting glucose in obese pregnant women.

176 circulating metabolites that correlate with fasting glucose in the Erasmus Rucphen Family (ERF) stud

177 SLC5A1 showed a significant association with fasting glucose in the expected opposing direction.

178 Fasting glucose increased in the tesamorelin group at 2

179 The markers examined included fasting glucose, insulin, adiponectin, and glycated albu

180 NP, was inversely associated with adiposity, fasting glucose, insulin, and cholesterol but positively

181 measurements of visceral fat mass; levels of fasting glucose, insulin, and fructosamine; older age; n

182 cted an epigenome-wide association study for fasting glucose, insulin, and homeostasis model assessme

183 asis model assessment of insulin resistance; fasting glucose, insulin, and lipids; body mass index (B

184 tion, routine biochemical parameters such as fasting glucose, insulin, total cholesterol, high-densit

185 rate that AMPK is unnecessary for normal 5-h fasting glucose kinetics and AICAR-mediated inhibition o

186 .2%, -0.7%); HC diet: -1.0% (-1.3%, -0.8%)], fasting glucose [LC diet: -0.7 mmol/L (-1.3, -0.1 mmol/L

187 We defined diabetes as a fasting glucose level >/=126 mg/L (or >/=200 mg/L for th

188 ntly of this, with a steeper increase of the fasting glucose level (beta=131; 95% CI 38-225) during f

189 yslipidemia in 55 patients (25.1%), impaired fasting glucose level in 7 patients (3.2%), and glucose

190 Diabetes was defined as a fasting glucose level of 126 mg/dL or higher, a 2-hour g

191 t loss, bleeding on probing, gingival index, fasting glucose level, and Homeostasis Model Assessment

192 creasing levels of alanine aminotransferase, fasting glucose level, hypertension (each P < .01), and

193 tolic blood pressure, diabetes mellitus, and fasting glucose level.

194 efit for cardiometabolic outcomes, including fasting glucose level.

195 ody mass index, systolic blood pressure, and fasting glucose level.

196 rends in HbA1c categories were compared with fasting glucose levels (>/=7.0 mmol/L [>/=126 mg/dL] and

197 mmol/L [P = .003]) and attenuated changes in fasting glucose levels (26 weeks: 1 +/- 16 mg/dL vs 5 +/

198 0%), elevated blood pressure (49%), impaired fasting glucose levels (26%), and diabetes mellitus (14%

199 = .01) but were less likely to have impaired fasting glucose levels (adjusted relative risk = 0.58 [9

200 abetes mellitus, and individuals with normal fasting glucose levels (controls).

201 r the remission of MetS identified that only fasting glucose levels (OR = 13.4; P = 0.01) and duratio

202 including survival, bodyweight, food intake, fasting glucose levels and age-related morbidity.

203 we show that hepatic GCN5L1 ablation reduces fasting glucose levels and blunts hepatic gluconeogenesi

204 Fasting glucose levels and carotid ultrasonography measu

205 s deletion of TXNIP in Agrp neurons improved fasting glucose levels and glucose tolerance independent

206 Reductions in fasting glucose levels and hemoglobin A1c were greater a

207 mice demonstrated a significant decrease in fasting glucose levels and insulin response to a glucose

208 production of GS-HNE associated with higher fasting glucose levels and moderately impaired glucose t

209 n glucose utilization and displayed elevated fasting glucose levels and severely impaired glucose tol

210 ugh which ADCY5 gene polymorphisms influence fasting glucose levels and T2D risk, while exerting more

211 Increasing fasting glucose levels at 1, 4, or 12 months after trans

212 0.3 vs. 2.2 +/- 0.44 kg/m(2) in persons with fasting glucose levels below and above the median, respe

213 AG infusion raised fasting glucose levels but had no effect on fasting plas

214 calibrated HbA1c levels than when defined by fasting glucose levels but has increased from 5.8% in 19

215 iabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in

216 miR administration lowered random as well as fasting glucose levels in diabetic mice.

217 ADRA2A (rs10885122) associated with elevated fasting glucose levels in genome-wide association studie

218 At 12 months, fasting glucose levels in the control group had increase

219 Higher fasting glucose levels may amplify obesity-risk in FTO c

220 Persons aged 18 to 75 years with fasting glucose levels of 12.5 mmol/L or less (</=225 mg

221 Variants associated with type 2 diabetes and fasting glucose levels reside in introns of ADCY5, a gen

222 sitivity C-reactive protein levels, impaired fasting glucose levels, dyslipidemia, elevated blood pre

223 The risk of impaired fasting glucose levels, elevated blood pressure, and ele

224 ApoA-I tg mice exhibited lower fasting glucose levels, improved glucose tolerance test,

225 variants were significantly associated with fasting glucose levels, including a nonsynonymous coding

226 ], and 3 suggestive QTLs were identified for fasting glucose levels.

227 otic medications can lose weight and improve fasting glucose levels.

228 and secretion without a detectable change in fasting glucose levels.

229 ession QTL and is negatively correlated with fasting glucose levels.

230 onizes the action of glucagon, thus reducing fasting glucose levels.

231 ffective despite improving plasma lipids and fasting glucose levels.

232 so underwent measurements of height, weight, fasting glucose, lipid, and PCB congener levels and veri

233 fication on high-fat diet without changes in fasting glucose, lipids, or body composition.

234 or more cardiometabolic abnormalities (high fasting glucose, low high-density lipoprotein cholestero

235 blood pressure <120/80 mm Hg, and untreated fasting glucose <100 mg/dL) in the absence of clinical c

236 ined as having blood pressure <120/80 mm Hg, fasting glucose <100 mg/dl, glycosylated hemoglobin <5.7

237 and untreated blood pressure <140/90 mm Hg, fasting glucose <126 mg/dl, total cholesterol <240 mg/dl

238 >40 mg/dl, and triglycerides <150 mg/dl; 4) fasting glucose <126 mg/dl; 5) nonsmoking status; 6) bod

239 Subjects were classified as having normal fasting glucose (<100 mg/dl and no hypoglycemic medicati

240 arter mile) was associated with increases in fasting glucose (mean = 0.22 mg/dL, 95% confidence inter

241 mg/dL]; P = .03), but changes at 6 months in fasting glucose (mean change, 4 mg/dL [95% CI, -2 to 10

242 protein electrophoresis with immunofixation, fasting glucose measurement, and glucose tolerance test.

243 letters, pharmacy dispensing data, and serum fasting glucose measurements taken at the study centre (

244 ntrast, HOMA-IR ([fasting insulin (muU/mL) x fasting glucose (mmol)]/22.5) did not detect reduced sen

245 ostasis model assessment [HOMA] index > 2.8, fasting glucose [mmol/L] x insulin [mU/L]/22.5; P(intera

246 Eight subjects with normal fasting glucose (NFG) and eight subjects with IFG receiv

247 ere defined on the basis of WHO criteria for fasting glucose (normoglycaemia: </=6.0 mmol/L; prediabe

248 onsidered type 2 diabetes (T2D, NSNPs = 49), fasting glucose (NSNPs = 36), insulin resistance (NSNPs

249 asting glucose, with a mean +/- SD change in fasting glucose of -1.1 +/- 8.4 mg/dL compared with an i

250 -C of 1.35 (CI, 1.26-1.45), and for impaired fasting glucose of 1.31 (CI, 1.05-1.64).

251 15 male subjects with HbA1c of 5.7 +/- 0.1%, fasting glucose of 114 +/- 3 mg/dL, and 2-h glucose of 1

252 ficant decreases in lipid profiles and serum fasting glucose of patients with obesity.

253 gh-fat diet to regain normal body weight and fasting glucose, olfactory dysfunctions are retained.

254 potentially functional variants influencing fasting glucose or FI levels.

255 re attenuated with additional adjustment for fasting glucose or HbA1c.

256 the inclusion criteria (NAFLD with impaired fasting glucose or impaired glucose tolerance) and were

257 al glucose tolerance and those with impaired fasting glucose or impaired glucose tolerance.

258 have diabetes and another 37% have impaired fasting glucose or impaired glucose tolerance.

259 tolerance, and 21 participants had impaired fasting glucose or impaired glucose tolerance.

260 red meat with genetic risk score related to fasting glucose or insulin resistance on fasting glucose

261 modified by genetic loci known to influence fasting glucose or insulin resistance.

262 R3527Q variant and impaired fasting glucose, fasting glucose or insulin, or oral glucose tolerance te

263 ssociated with the clinical glycemic markers fasting glucose or the HbA1c, and vice versa.

264 % confidence interval, 1.2-2.0) and elevated fasting glucose (OR, 1.6; 95% confidence interval, 1.1-2

265 BMI >/=27.5 kg/m(2) ), diabetes or impaired fasting glucose (OR, 4.45; CI, 1.10-30.0), and PNPLA3 14

266 actors (hypertension, dyslipidemia, impaired fasting glucose, or the metabolic syndrome).

267 n intronic variant in MTNR1B associated with fasting glucose (p = 3.7E-08); variants in the APOA5-ZNF

268 PPP1R3B was associated with higher levels of fasting glucose (P = 7.70 x 10-7) and fasting insulin (P

269 as assessed by RDI score was associated with fasting glucose (R = 0.325, p = 0.001) and fasting insul

270 The fasting glucose-raising allele near PDX1, a known key in

271 Thirty type 2 diabetes or fasting glucose-raising alleles were associated with a m

272 which, through reduction in postprandial and fasting glucose, reduces HbA1c.

273 Additional adjustment for fasting glucose rendered both coefficients insignificant

274 e red meat diet (P < 0.01) with no change in fasting glucose resulting in a decrease in insulin sensi

275 tein-cholesterol ratio TG/HDL-C, or impaired fasting glucose (serum glucose >/=110 mg/dL) to traditio

276 during pregnancy did not influence maternal fasting glucose, the metabolic profile, or pregnancy out

277 s into the regulation of fasting insulin and fasting glucose through the use of gene expression micro

278 by significantly lower levels of prolactin, fasting glucose, total cholesterol, and triglycerides th

279 te, smoking status, systolic blood pressure, fasting glucose, total cholesterol, antihypertensive med

280 AL was measured using eight biomarkers: fasting glucose, total cholesterol, high-density lipopro

281 Compared with C, HFr significantly increased fasting glucose, total TG, TRL-TG concentrations, and ap

282 Fasting glucose, triglycerides, uric acid, and bilirubin

283 The mVEGF(-/-) mice had augmented fasting glucose turnover.

284 tin and hematocrit levels increased more and fasting glucose, uric acid, and triglyceride levels decr

285 d rare variants in 5 gene regions with FI or fasting glucose using the sequence kernel association te

286 n a subgroup of 512 participants with normal fasting glucose values at baseline, incidence of the com

287 onal 50-g serving of processed meat per day, fasting glucose was 0.021 mmol/L (95% CI: 0.011, 0.030 m

288 The prevalence of abnormal fasting glucose was 40.2%.

289 Mean fasting glucose was 5.29 mmol/L (SD 0.66), mean fasting

290 Fasting glucose was lower after RYGB than after LS/IMM,

291 R 3.01, 95% CI 1.60 to 5.65), while impaired fasting glucose was not (OR 1.55, 95% CI 0.70 to 3.44).

292 The adjusted ORs of LGA per 1 SD fasting glucose were 1.22 (95% CI 1.08-1.38) in white Br

293 Full montage home-polysomnography and fasting glucose were available on all participants.

294 , systolic and diastolic blood pressure, and fasting glucose were measured.

295 , systolic and diastolic blood pressure, and fasting glucose were measured.

296 Increases in fasting glucose were observed within both groups but wer

297 lipoprotein cholesterol, triglycerides, and fasting glucose were significantly greater after duodena

298 m glycemic changes; and the association with fasting glucose were significantly modified by postpartu

299 prediabetes (insulin resistance and impaired fasting glucose) were higher among persons with greater

300 rticipants taking KCl had stable or improved fasting glucose, with a mean +/- SD change in fasting gl